Simcere Pharmac Grp Stock Current Asset
| S2P Stock | EUR 0.81 0.00 0.00% |
SIMCERE PHARMAC GRP fundamentals help investors to digest information that contributes to SIMCERE PHARMAC's financial success or failures. It also enables traders to predict the movement of SIMCERE Stock. The fundamental analysis module provides a way to measure SIMCERE PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SIMCERE PHARMAC stock.
SIMCERE |
SIMCERE PHARMAC GRP Company Current Asset Analysis
SIMCERE PHARMAC's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, SIMCERE PHARMAC GRP has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The current asset for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
SIMCERE Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0344 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.1 % | |||
| Shares Outstanding | 2.66 B | |||
| Shares Owned By Insiders | 69.20 % | |||
| Shares Owned By Institutions | 4.70 % | |||
| Revenue | 5.58 B | |||
| Gross Profit | 3.92 B | |||
| EBITDA | 743.59 M | |||
| Book Value Per Share | 2.31 X | |||
| Earnings Per Share | 0.05 X | |||
| Number Of Employees | 6.54 K | |||
| Beta | 0.48 | |||
| Market Capitalization | 3.75 B | |||
| Annual Yield | 0.02 % | |||
| Last Dividend Paid | 0.15 |
About SIMCERE PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SIMCERE PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SIMCERE PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SIMCERE PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SIMCERE Stock
SIMCERE PHARMAC financial ratios help investors to determine whether SIMCERE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SIMCERE with respect to the benefits of owning SIMCERE PHARMAC security.